Co-Authors
This is a "connection" page, showing publications co-authored by Alessandro Armuzzi and Antonio Gasbarrini.
Connection Strength
1.174
-
The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. Inflamm Bowel Dis. 2020 08 20; 26(9):1306-1314.
Score: 0.225
-
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. United European Gastroenterol J. 2020 08; 8(7):775-781.
Score: 0.221
-
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. Expert Rev Clin Immunol. 2018 09; 14(9):751-759.
Score: 0.196
-
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The "EPIMICI - San Marino" study. Dig Liver Dis. 2019 02; 51(2):218-225.
Score: 0.196
-
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. PLoS One. 2017; 12(10):e0186575.
Score: 0.185
-
The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center. Endosc Int Open. 2020 Jul; 8(7):E980-E984.
Score: 0.056
-
Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-a on the Liver. Int J Mol Sci. 2018 Jul 27; 19(8).
Score: 0.049
-
Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease. Dig Dis. 2018; 36(3):184-193.
Score: 0.047